Key Takeaways
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist, sold under the brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management).
- Retatrutide is an investigational triple-hormone-receptor agonist that additionally targets the glucagon receptor. It is not FDA-approved and remains in Phase 3 clinical trials.
- In matched-duration trial comparisons, retatrutide has shown greater average body weight reduction than tirzepatide, though no completed head-to-head Phase 3 trial exists yet.
- Tirzepatide can be legally prescribed today by a licensed healthcare provider. Retatrutide cannot currently be legally prescribed, sold as a finished drug product, or used outside of registered clinical trials.
- Eli Lilly's New Drug Application for retatrutide is expected in late 2026 or early 2027, with potential FDA approval realistically landing in late 2027 or 2028.
What Is Tirzepatide?
Tirzepatide is a once-weekly injectable dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist developed by Eli Lilly. It is FDA-approved and marketed under two brand names depending on the indication: Mounjaro for type 2 diabetes and Zepbound for chronic weight management in adults with obesity or overweight and at least one weight-related condition.
Featured Products
By activating both the GIP and GLP-1 receptors, tirzepatide slows gastric emptying, increases feelings of fullness, and improves insulin sensitivity and glucose control. In the pivotal SURMOUNT-1 trial, participants achieved average body weight reductions of roughly 22.5% at 72 weeks on the highest dose, figures that helped establish tirzepatide as one of the most effective anti-obesity medications on the market at the time of its approval.
What Is Retatrutide?
Retatrutide is Eli Lilly's investigational "triple agonist" peptide. In addition to activating the GIP and GLP-1 receptors like tirzepatide, retatrutide also activates the glucagon receptor — making it the first compound of its kind to reach late-stage clinical development for obesity and related metabolic conditions.
The added glucagon receptor activity is believed to increase energy expenditure alongside appetite suppression, which researchers think may explain the larger average weight reductions observed in retatrutide's clinical trials compared with dual-agonist compounds. As of mid-2026, retatrutide remains an investigational drug. It has not been approved by the FDA, the European Medicines Agency, the UK's MHRA, or any other major regulator, and it is not legally available for prescription or purchase as a finished medical product.
Mechanism of Action: How They Compare
The core distinction between the two compounds comes down to receptor targets:
Feature | Tirzepatide | Retatrutide |
|---|---|---|
Receptor targets | GIP + GLP-1 (dual agonist) | GIP + GLP-1 + Glucagon (triple agonist) |
Developer | Eli Lilly | Eli Lilly |
Dosing schedule | Once weekly, subcutaneous injection | Once weekly, subcutaneous injection |
Primary mechanism | Appetite suppression, delayed gastric emptying, improved insulin sensitivity | Appetite suppression plus increased energy expenditure via glucagon receptor activity |
Brand names | Mounjaro (T2D), Zepbound (obesity) | None assigned yet |
Clinical Trial Data: What the Evidence Shows
Direct head-to-head Phase 3 data comparing retatrutide and tirzepatide does not yet exist. The comparisons below are drawn from each compound's own trial program and should be read as matched-duration comparisons rather than a controlled head-to-head study.
Tirzepatide (SURMOUNT-1)
- Average body weight reduction of approximately 22.5% at 72 weeks on the highest studied dose in adults with obesity or overweight.
- FDA-approved based on this and subsequent trials for both type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).
Retatrutide (TRIUMPH Phase 3 Program)
- Phase 2 data published in the New England Journal of Medicine (2023) showed participants lost up to 24.2% of body weight at 48 weeks on the 12 mg dose.
- TRIUMPH-4, the first completed Phase 3 readout (adults with obesity or overweight and knee osteoarthritis, without diabetes), reported average weight loss of up to 28.7% (about 32.3 kg / 71.2 lbs) at 68 weeks.
- TRANSCEND-T2D-1, a Phase 3 trial in adults with type 2 diabetes, reported average A1C reductions of up to 2.0% alongside significant weight loss at 40 weeks.
- Seven additional Phase 3 TRIUMPH readouts covering obesity, sleep apnea, MASLD (fatty liver disease), and cardiovascular outcomes are expected throughout 2026.
Featured Snippet Answer: Is retatrutide more effective than tirzepatide? In matched-duration trial comparisons, retatrutide has shown greater average weight loss (up to 28.7% at 68 weeks) than tirzepatide (about 22.5% at 72 weeks). However, no completed head-to-head Phase 3 trial exists, so this is an indirect comparison, not a direct one. |
Regulatory and Legal Status
This is one of the most important — and most frequently misunderstood — differences between the two compounds.
Tirzepatide | Retatrutide | |
|---|---|---|
FDA approval status | Approved (Mounjaro: 2022; Zepbound: 2023) | Not approved — investigational, Phase 3 |
Legally prescribable | Yes, by a licensed healthcare provider | No, outside of registered clinical trials |
Available as finished drug product for sale | Yes, through licensed pharmacies | No |
Expected regulatory milestone | Already on market | NDA submission expected Q4 2026–Q1 2027; approval realistically late 2027–2028 |
Because retatrutide has not completed the FDA approval process, it cannot legally be prescribed, marketed as a treatment, or sold as a finished medical product for individual use in the United States. Any use of retatrutide currently occurs exclusively within registered, IRB-approved clinical trials under medical supervision.
Safety and Side Effect Profile
Both compounds belong to the same general drug class and share a broadly similar side effect profile, largely gastrointestinal in nature.
- Nausea, vomiting, and diarrhea are the most commonly reported side effects for both compounds, particularly during dose escalation.
- Retatrutide's Phase 3 safety data (TRIUMPH-4) has been described as qualitatively similar to tirzepatide and semaglutide, though some trial reporting notes a somewhat higher rate of GI adverse events with retatrutide's added glucagon receptor activity.
- Because retatrutide is still investigational, its long-term safety profile is less established than tirzepatide's, which has several years of real-world post-marketing data.
Anyone considering treatment with an FDA-approved GLP-1/GIP therapy like tirzepatide should do so only under the guidance of a licensed healthcare provider, who can evaluate individual health history, monitor for side effects, and adjust dosing appropriately.
Retatrutide vs Tirzepatide: Side-by-Side Summary
Category | Tirzepatide | Retatrutide |
|---|---|---|
Class | Dual GIP/GLP-1 agonist | Triple GIP/GLP-1/Glucagon agonist |
Development stage | Approved, on market | Phase 3 clinical trials |
Reported weight loss (matched duration) | ~22.5% at 72 weeks | ~28.7% at 68 weeks |
Legal access | Prescription only | Clinical trial enrollment only |
Long-term safety data | Established (post-market) | Limited (trial-stage only) |
Common Misconceptions
"Research use only" means it's legal to use personally
Labeling a compound as "for research use only" describes its regulatory classification, not its safety or legality for personal use. Investigational drugs like retatrutide have not completed the safety and efficacy review required for human use outside of a clinical trial setting.
"Retatrutide is just a stronger version of tirzepatide"
Retatrutide isn't simply a higher dose of the same mechanism. It adds an entirely separate receptor target — the glucagon receptor — which is believed to work through a different biological pathway (increased energy expenditure) rather than only suppressing appetite.
"Phase 3 trial success means FDA approval is guaranteed"
Positive Phase 3 topline results are a major milestone, but they are followed by a full New Drug Application review process, which typically takes 10–12 months once submitted and can result in requests for additional data.
Frequently Asked Questions
What is the main difference between retatrutide and tirzepatide?
Tirzepatide activates two hormone receptors (GIP and GLP-1) and is FDA-approved. Retatrutide activates three receptors (GIP, GLP-1, and glucagon) and remains an investigational drug in Phase 3 clinical trials.
Is retatrutide FDA-approved?
No. As of mid-2026, retatrutide has not been approved by the FDA or any major regulator. Eli Lilly's New Drug Application is expected in late 2026 or early 2027.
Is tirzepatide FDA-approved?
Yes. Tirzepatide is FDA-approved and sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
Which causes more weight loss, retatrutide or tirzepatide?
In separate matched-duration trials, retatrutide has shown greater average weight loss (up to 28.7% at 68 weeks) than tirzepatide (about 22.5% at 72 weeks), but no completed head-to-head trial exists.
Can I legally buy retatrutide for personal use?
No. Retatrutide cannot currently be legally prescribed or sold as a finished drug product for individual use. It is only available within registered clinical trials.
What does 'triple agonist' mean?
A triple agonist is a compound that activates three different hormone receptors — in retatrutide's case, GIP, GLP-1, and glucagon — compared with a dual agonist like tirzepatide, which activates two.
When will retatrutide be approved?
Eli Lilly expects to submit its New Drug Application in Q4 2026 or Q1 2027. Given standard review timelines, approval would realistically occur in late 2027 or 2028.
Does retatrutide help with conditions besides obesity?
Yes. Ongoing Phase 3 trials are evaluating retatrutide for type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and MASLD (fatty liver disease).
What are the side effects of tirzepatide and retatrutide?
Both compounds share similar gastrointestinal side effects, including nausea, vomiting, and diarrhea, particularly during dose escalation. Retatrutide's long-term safety data is less established since it remains in clinical trials.
Is retatrutide safe?
Retatrutide's Phase 3 safety data so far appears broadly similar to tirzepatide and semaglutide, but because it hasn't completed the FDA review process, its full safety profile is not yet established for general use.
What is the brand name for retatrutide?
Eli Lilly has not yet assigned a brand name to retatrutide, as it has not been approved for marketing.
How is retatrutide administered in clinical trials?
In its clinical trials, retatrutide is administered as a once-weekly subcutaneous injection, similar to tirzepatide.
What trials make up the retatrutide development program?
Retatrutide's Phase 3 program is called TRIUMPH, and includes multiple trials covering obesity, type 2 diabetes (TRANSCEND-T2D), sleep apnea, osteoarthritis, and cardiovascular outcomes.
Can a doctor prescribe retatrutide off-label?
No. Because retatrutide has not received FDA approval for any indication, it cannot legally be prescribed off-label the way an approved drug can.
